- German startup SWARM Biotactics revealed that its bioelectronic cyborg insect swarms have been field-tested and deployed with paying NATO customers including the Bundeswehr.
- The company’s systems combine living insects with neural interfaces, sensors, and secure communications to create coordinated autonomous reconnaissance platforms.
German defense technology startup SWARM Biotactics has revealed that its bioelectronic insect-based robotic systems have been field-tested and deployed with paying NATO customers, according to a Feb. 25 statement by company Chief Executive Officer Stefan Wilhelm.
The announcement confirms operational progress for programmable cyborg insect swarms developed for sensing and reconnaissance missions.
According to Wilhelm, the capability did not exist a year earlier and has progressed rapidly from concept to operational deployment. “One year ago, this didn’t exist,” he said, describing the systems as “programmable cyborg insect swarms — built, field-tested, and deployed with paying NATO customers.”
The company stated that the systems consist of living organisms controlled through bioelectronic neural interfaces equipped with sensors, onboard artificial intelligence processing, and secure communications links. Wilhelm said the platforms are capable of moving as coordinated units while carrying modular payloads designed for mission-specific tasks.
“What you’re seeing is real. Living organisms, controlled through bioelectronic neural interfaces, carrying sensors, edge AI, and secure comms. Moving as a coordinated unit. Scaling through breeding, not factories,” Wilhelm said in the statement.
SWARM Biotactics reported that within 12 months of its founding, the company expanded to more than 40 engineers and scientists operating across Germany and the United States. The firm also confirmed paying defense customers, including Germany’s Bundeswehr, and stated that systems have undergone field validation in both European and U.S. operational environments.
The company said it has developed a full-stack technology architecture encompassing neural interfaces, swarm autonomy software, modular payload integration, and mission-control systems. Wilhelm stated, “No other company in the Western world is building this.”
Bio-robotic systems differ from conventional unmanned platforms by integrating biological mobility with electronic control systems. Instead of relying on mechanical propulsion, the approach leverages natural insect locomotion while adding digital command, sensing, and communication capabilities.
Such systems may offer advantages in confined or complex environments where small size, low acoustic signature, and biological movement patterns allow access to areas difficult for traditional drones. Payloads can include sensing devices and communications equipment intended for reconnaissance or situational awareness tasks.
The company emphasized that scaling production relies on biological reproduction rather than conventional manufacturing lines. Wilhelm described the concept as a different model of technological growth, stating the company is “not building a better drone” but pursuing “a different scaling law for physical intelligence – one where capability compounds through biology, not engineering complexity.”
SWARM Biotactics also noted that competing nations are investing in bio-robotics research for military applications. Wilhelm said, “Meanwhile, adversaries are investing heavily in bio-robotics for military applications. The capability gap is real, and it’s closing — from the other side.”
The company reported attracting approximately €13 million ($15.36 million) in investment funding to support development and expansion. The startup operates as a German-based firm with engineering activity in both Europe and the United States.
Background efforts in autonomous systems development have largely focused on aerial drones and ground robotics, while biologically integrated platforms have remained largely experimental. The company’s statement indicates a shift toward field validation and early operational adoption rather than laboratory research alone.